- Allogene Therapeutics press release ( NASDAQ: ALLO ): Q2 GAAP EPS of -$0.52 beats by $0.08 .
- Revenue of $0.09M (+125.0% Y/Y) beats by $0.07M .
- Ended Second Quarter with $686 Million in Cash, Cash Equivalents and Investments.
- While the Company anticipates spending to increase in the second half relative to the first half of 2022, it now expects full year GAAP Operating Expenses to be at the low end of the previous range of $360 million and $390 million. This includes estimated non-cash stock-based compensation expense of $90 million to $100 million and excluding any impact from potential business development activities. Cash burn for 2022 is now expected to be approximately $250 million.
For further details see:
Allogene Therapeutics GAAP EPS of -$0.52 beats by $0.08, revenue of $0.09M beats by $0.07M